Presentation is loading. Please wait.

Presentation is loading. Please wait.

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry  Bruce Strober,

Published byBirger Gulbrandsen Modified over 6 years ago

Similar presentations

Presentation on theme: "Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry  Bruce Strober,"— Presentation transcript:

1 Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry  Bruce Strober, MD, PhD, Chitra Karki, MPH, Marc Mason, MS, Ning Guo, MS, Stacey H. Holmgren, PharmD, Jeffrey D. Greenberg, MD, MPH, Mark Lebwohl, MD  Journal of the American Academy of Dermatology  Volume 78, Issue 2, Pages (February 2018) DOI: /j.jaad Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Corrona sites from inception of the Psoriasis Registry.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Patient disposition flowchart. *nonbiologics are cyclosporine and methotrexate. IL, interleukin; TNF, tumor necrosis factor. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry  Bruce Strober,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 

Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD 

Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD 
Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Pediatric teledermatology: Observations based on 429 consults

Pediatric teledermatology: Observations based on 429 consults
An enlarging, ulcerated scalp nodule

An enlarging, ulcerated scalp nodule
Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry  David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Similar presentations

Ads by Google